CDKL3 and osteosarcoma: Recent studies have found abnormal expression of CDKL3 in several cancers, particularly osteosarcoma, esophageal squamous cell carcinoma, colorectal cancer, glioma, and cholangiocarcinoma [6, 8, 10–12].